Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Sigma-Aldrich Licenses From NeuroSurvival Technologies a Leading Marker for Molecular Imaging of Apoptosis in Vivo

Abstract:
Sigma-Aldrich(TM) and NeuroSurvival Technologies Ltd. (NST) announced today that they have signed a licensing agreement for a leading marker, developed by NST, for molecular imaging of apoptosis in vitro and in vivo in animals. The marker, developed by NST, will be manufactured and marketed by Sigma-Aldrich under the commercial name Apo-TRACE(TM) (www.sigma.com/apotrace). Apo-TRACE(TM) is a member of a family of proprietary small molecules developed by NST that target apoptosis. Another molecule of the family, ApoSense(TM)-PET, is in clinical trials for imaging apoptosis in vivo in humans with PET (positron emitting tomography) and is not part of this agreement.

Sigma-Aldrich Licenses From NeuroSurvival Technologies a Leading Marker for Molecular Imaging of Apoptosis in Vivo

ST. LOUIS, MO | Posted on February 27th, 2008

Apoptosis (programmed cell death) is a fundamental biological process of cell "suicide", inherent in every cell in body, and its discovery is regarded as one of the major recent revolutions in biology and medicine. Apoptosis has an important role in almost any medical disorder, and its control may hold the promise for substantial advances in medical care for a wide array of medical disorders, ranging from cancer, myocardial infarction and cerebral stroke, to neurodegenerative disorders such as Alzheimer's disease.

Respectively, extensive scientific work is continuously being performed in the field of apoptosis worldwide, involving thousands of research groups, and generating over 17,000* peer-reviewed scientific papers in 2006 alone. Apo-TRACE is a unique and novel solution to the need of researchers for imaging of apoptosis in vivo, in the living organism. As such, it may substantially contribute to advancing preclinical research in variety of fields. Upon a simple intravenous administration, Apo-TRACE selectively targets cells undergoing apoptosis from the early stages of the death process, and, through its fluorescent properties, marks the apoptotic cells, thus enabling easy and accurate detection in vivo of this important cell death process. Thus, by substantially facilitating apoptosis research in vivo, Apo-TRACE offers a breakthrough in advancing apoptosis related research in a range of fields in biology and medicine. Apo-TRACE is available for purchase from Sigma-Aldrich as of January 2008. Once the ApoSense(TM)-PET molecule also becomes commercially available from NST, apoptosis research in vivo will continue into the clinic and become a valuable biomarker for development and testing of new therapeutic agents.

* Based on PubMed database search.

####

About Sigma-Aldrich
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 36 countries and has 7,900 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at www.sigma-aldrich.com.

About NST: NST NeuroSurvival Technologies is a clinical stage molecular imaging and drug development company, focused on the introduction of novel agents based on the identification and targeting of cells undergoing apoptosis (programmed cell death). NST has developed the ApoSense(TM) technology -- A set of proprietary compounds with demonstrated ability to identify, bind and accumulate within apoptotic (dying) cells in vivo. This technology addresses a huge market of unmet research and clinical need across a range of molecular imaging and therapeutic applications. ApoSense(TM)-PET, NST's lead compound for clinical molecular imaging of apoptosis in vivo, using the PET modality, is currently in phase II clinical studies.

Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Companies' expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Companies' operations and conditions in the markets the Companies serve. The Companies do not undertake any obligation to update these forward-looking statements.

Apo-TRACE is a trademark of Sigma-Aldrich

ApoSense is a trademark of NST NeuroSurvival Technologies Ltd.

For more information, please click here

Contacts:
Sigma-Aldrich Corporate Offices
Sigma-Aldrich
3050 Spruce St.
St. Louis, MO 63103
1-800-521-8956

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

SEMATECH to Showcase Innovation and Advances in Manufacturing at SEMICON Japan 2014: SEMATECH experts will share the latest techniques, emerging trends and best practices in advanced manufacturing strategies and methodologies November 26th, 2014

Australian startup creates world’s first 100% cotton hydrophobic T-Shirts November 26th, 2014

The mysterious 'action at a distance' between liquid containers November 26th, 2014

'Giant' charge density disturbances discovered in nanomaterials: Juelich researchers amplify Friedel oscillations in thin metallic films November 26th, 2014

Nanomedicine

Vegetable oil ingredient key to destroying gastric disease bacteria: In mice, therapeutic nanoparticles dampen H. pylori bacteria and inflammation that lead to ulcers and gastric cancer November 25th, 2014

Research reveals how our bodies keep unwelcome visitors out of cell nuclei November 24th, 2014

ASU, IBM move ultrafast, low-cost DNA sequencing technology a step closer to reality November 24th, 2014

An Inside Job: UC-Designed Nanoparticles Infiltrate, Kill Cancer Cells From Within November 24th, 2014

Announcements

SEMATECH to Showcase Innovation and Advances in Manufacturing at SEMICON Japan 2014: SEMATECH experts will share the latest techniques, emerging trends and best practices in advanced manufacturing strategies and methodologies November 26th, 2014

Australian startup creates world’s first 100% cotton hydrophobic T-Shirts November 26th, 2014

The mysterious 'action at a distance' between liquid containers November 26th, 2014

'Giant' charge density disturbances discovered in nanomaterials: Juelich researchers amplify Friedel oscillations in thin metallic films November 26th, 2014

Patents/IP/Tech Transfer/Licensing

Dicerna Announces License Agreement with Tekmira to Advance Dicerna’s PH1 Development Program November 17th, 2014

First genetic-based tool to detect circulating cancer cells in blood: NanoFlares light up individual cells if breast cancer biomarker is present November 17th, 2014

Ki-Bum Lee Patents Technology To Advance Stem Cell Therapeutics November 13th, 2014

'Direct writing' of diamond patterns from graphite a potential technological leap November 5th, 2014

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More












ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE